MREO News and Press, Mereo BioPharma Group From 03/30/22

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Gainers: Adagio Therapeutics (ADGI) +47%. Insignia Systems (ISIG) +26%. Romeo Power (RMO) +24%. Vir Biotechnology (VIR) +20%. TMC the metals company (TMC) +19%. Arhaus (ARHS) +19%. Ambac Financial Group (AMBC) +18%. Pear Therapeutics (PEAR) +17%. Vyant Bio (VYNT) +16%. Sportradar (SRAD) +16%....

Gainers: Adagio Therapeutics (ADGI) +48%. Vyant Bio (VYNT) +23%. Vir Biotechnology (VIR) +19%. Sonoma Pharmaceuticals (SNOA) +15%. Syros Pharmaceuticals (SYRS) +15%. Losers: Revelation Biosciences (REVB) -40%. UpHealth (UPH) -29%. The Valens (VLNS)...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

LONDON and REDWOOD CITY, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a virtual R&...

LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hylan...

LONDON and REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight,...

Mereo BioPharma (NASDAQ:MREO) perks up 1.8% premarket after announcing top-line data from a Phase 1b/2 COSTA clinical trial evaluating alvelestat in hospitalized COVID-19 Respiratory Disease patients. Enrolled subjects received alvelestat or matched placebo, twice daily, for 5 ...

Alvelestat reported safe and well-tolerated in patients with COVID-19 Alvelestat , on top of standard of care resulted in a more rapid time to improvement in WHO Disease Severity score of >=2 in the first 5-7 days compared to placebo plus standard of...

Penny Stocks to Watch as 2021 Comes to an End As 2021 comes to an end, investors continue to search for the best penny stocks to buy . Although it can be challenging given the sheer number of penny stocks out there and factors at play, there are many ways to make money with ...